Align Technology, Inc. (NASDAQ: ALGN) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 30.15 | EPS (ttm) | 5.76 | Insider Own | 1.02% | Shs Outstand | 71.62M | Perf Week | 2.66% |
| Market Cap | 12.44B | Forward P/E | 13.87 | EPS next Y | 12.52 | Insider Trans | -1.09% | Shs Float | 66.91M | Perf Month | -2.53% |
| Enterprise Value | 12.44B | PEG | - | EPS next Q | 2.81 | Inst Own | - | Short Float | 7.21% | Perf Quarter | 3.13% |
| Income | 414.16M | P/S | 3.00 | EPS this Y | 95.83% | Inst Trans | - | Short Ratio | 4.63 | Perf Half Y | -1.12% |
| Sales | 4.14B | P/B | - | EPS next Y | 11.00% | ROA | 6444.45% | Short Interest | 4.83M | Perf YTD | 11.21% |
| Book/sh | - | P/C | 16.42 | EPS next 5Y | 10.80% | ROE | 13.60% | 52W High | 202.73 -13.36% | Perf Year | 26.85% |
| Cash/sh | - | P/FCF | 16.46 | EPS past 3/5Y | 7.02% -24.09% | ROIC | 8830.41% | 52W Low | 123.40 42.34% | Perf 3Y | -52.73% |
| Dividend Est. | - | EV/EBITDA | 15.82 | Sales past 3/5Y | 2.61% 10.30% | Gross Margin | 66.48% | Volatility | 3.18% 3.77% | Perf 5Y | -75.04% |
| Dividend TTM | - | EV/Sales | 3.00 | EPS Y/Y TTM | 2.49% | Oper. Margin | 13.33% | ATR (14) | 7.31 | Perf 10Y | 103.64% |
| Dividend Ex-Date | - | Quick Ratio | 1.28 | Sales Y/Y TTM | 3.53% | Profit Margin | 9.99% | RSI (14) | 49.57 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.40 | EPS Q/Q | 6.02% | SMA20 | -0.36% | Beta | 1.61 | Target Price | 203.50 |
| Payout | 0.00% | Debt/Eq | 0.03 | Sales Q/Q | 4.35% | SMA50 | -0.59% | Rel Volume | 0.84 | Prev Close | 173.66 |
| Employees | 20,290 | LT Debt/Eq | 0.02 | Earnings | Oct 28 | SMA200 | 3.52% | Avg Volume | 1.03M | Price | 175.65 |
| IPO Date | Jan 30, 2001 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.91% 0.40% | Net Debt/EBITDA | -0.00 | Volume | 869,858 | Change | 1.14% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-23-26 | Reiterated | UBS | Neutral | $186 → $189 |
| Jul-08-26 | Initiated | BMO Capital | Outperform | $209 |
| Apr-24-26 | Reiterated | Morgan Stanley | Equal Weight | $154 → $188 |
| Apr-21-26 | Reiterated | Piper Sandler | Overweight | $220 → $235 |
| Mar-17-26 | Upgrade | Barclays | Equal Weight → Overweight | |
| Feb-09-26 | Upgrade | HSBC | Hold → Buy | $200 |
| Feb-05-26 | Reiterated | Stifel Nicolaus | Buy | $200 → $210 |
| Feb-05-26 | Reiterated | Robert W. Baird | $205 → $218 | |
| Feb-05-26 | Reiterated | Piper Sandler | Overweight | $200 → $220 |
| Feb-05-26 | Reiterated | Wells Fargo | Overweight | $200 |
Align Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry. The company's operations are divided into two main business units: "Clear Aligner" and "Scanners and Services." The Clear Aligner segment offers a variety of solutions. Its comprehensive products include the full Invisalign treatment for teenage patients, designed to address complex orthodontic needs such as mandibular advancement, patient compliance tracking, and managing tooth eruption. It also features specialized Invisalign First Phase I and Phase 2 packages for younger children, typically aged seven to ten, who have mixed dentition (a combination of primary and permanent teeth). Beyond these, the segment provides non-comprehensive aligner options like Invisalign moderate, lite, express, and Invisalign Go. Additional non-case products include retention devices, fees for Invisalign training, and sales of ancillary items such as cleaning materials and adjustment tools used by dental practitioners during treatment. The Scanners and Services segment centers around the iTero scanner, a unified hardware platform offering various software applications for both restorative and orthodontic procedures. It supplies specialized restorative software to general dentists, prosthodontists, periodontists, and oral surgeons, as well as distinct software for orthodontists to manage digital patient records, perform diagnoses, and facilitate the fabrication of printed models and retainers. This segment also provides computer-aided design and manufacturing (CAD/CAM) services, along with supplementary products like disposable covers for the scanner wand and iTero models and dies. Furthermore, it includes third-party scanners and digital scan solutions, the Invisalign Outcome Simulator (a chair-side and cloud-based application for the iTero scanner), the Invisalign Progress Assessment tool, and TimeLapse technology, which enables clinicians to compare a patient's historical 3D scans against current data. Align Technology distributes its products worldwide, with a strong presence in the United States, Switzerland, and China. Founded in 1997, the company is headquartered in Tempe, Arizona.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,140 | 4,035 | 3,999 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 1,387 | 1,278 | 1,200 | — | — | — | — | — | — | |
| Gross Profit | 2,752 | 2,757 | 2,799 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,787 | 1,756 | 1,763 | — | — | — | — | — | — | |
| Research and Development | 377 | 370 | 364 | — | — | — | — | — | — | |
| Other Operating Expense | 37 | 15 | 65 | — | — | — | — | — | — | |
| Operating Income | 552 | 616 | 608 | — | — | — | — | — | — | |
| Interest Expense | 2 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 18 | -31 | 1 | — | — | — | — | — | — | |
| Net Income Before Taxes | 570 | 585 | 609 | — | — | — | — | — | — | |
| Income Taxes | 155 | 175 | 188 | — | — | — | — | — | — | |
| Consolidated Net Income | 414 | 410 | 421 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 414 | 410 | 421 | — | — | — | — | — | — | |
| Net Income | 414 | 410 | 421 | — | — | — | — | — | — | |
| EPS (Recurring) | 5.76 | 5.66 | 5.63 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 5.76 | 5.66 | 5.63 | — | — | — | — | — | — | |
| EPS (Diluted) | 5.76 | 5.65 | 5.62 | — | — | — | — | — | — | |
| EBITDA | 787 | 766 | 817 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 30.49 | 27.64 | 37.10 | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.01 | 2.83 | 3.91 | — | — | — | — | — | — | |
| Gross Margin | 66.47 | 68.33 | 69.99 | — | — | — | — | — | — | |
| Operating Margin | 13.33 | 15.27 | 15.20 | — | — | — | — | — | — | |
| Net Margin | 10.00 | 10.16 | 10.53 | — | — | — | — | — | — | |
| Shares Outstanding | 71 | 73 | 75 | — | — | — | — | — | — | |
| Market Capitalization | 12,471 | 11,399 | 15,638 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Conroy Kevin T | Director | May 20 '26 | Option Exercise | 0.00 | 1,745 | 0 | 3,553 | May 22 |
| MORROW GEORGE J | Director | May 20 '26 | Option Exercise | 0.00 | 1,745 | 0 | 5,036 | May 22 |
| Vitalone Britt J. | Director | May 20 '26 | Option Exercise | 0.00 | 1,443 | 0 | 1,443 | May 22 |
| Saia Andrea Lynn | Director | May 20 '26 | Option Exercise | 0.00 | 1,745 | 0 | 17,318 | May 22 |
| Poul Mojdeh | Director | May 20 '26 | Option Exercise | 0.00 | 1,745 | 0 | 3,553 | May 22 |
| Myong Anne | Director | May 20 '26 | Option Exercise | 0.00 | 1,745 | 0 | 9,830 | May 22 |
| SIEGEL SUSAN E | Director | May 20 '26 | Option Exercise | 0.00 | 1,745 | 0 | 10,723 | May 22 |
| LARKIN C RAYMOND JR | Director | May 20 '26 | Option Exercise | 0.00 | 2,326 | 0 | 27,454 | May 22 |
| Dallas Kevin J | Director | May 20 '26 | Option Exercise | 0.00 | 1,745 | 0 | 16,168 | May 22 |
| LACOB JOSEPH | Director | May 20 '26 | Option Exercise | 0.00 | 1,745 | 0 | 135,916 | May 22 |
| Coletti Julie Ann | EVP, CHIEF LEGAL & REGULATORY | Feb 20 '26 | Option Exercise | 0.00 | 11,728 | 0 | 13,163 | Feb 24 |
| HOGAN JOSEPH M | President and CEO | Feb 20 '26 | Option Exercise | 0.00 | 80,496 | 3 | 225,377 | Feb 24 |
| Morici John | EVP, CHIEF FINANCIAL OFFICER | Feb 20 '26 | Option Exercise | 0.00 | 15,696 | 0 | 16,085 | Feb 24 |
| Hockridge Stuart A | EVP, GLOBAL HR | Feb 20 '26 | Option Exercise | 0.00 | 8,620 | 0 | 16,102 | Feb 24 |
| Morici John | EVP, CHIEF FINANCIAL OFFICER | Feb 18 '26 | Sale | 189.31 | 7,969 | 1,508,646 | 8,237 | Feb 20 |